According to the lawsuit, Sanofi has failed to provide partner Regeneron adequate information regarding the sales of Dupixent ...

Sanofi in partnership with Regeneron to present 24 abstracts across approved and investigational medicines at AAAAI Annual Meeting in San Diego: Paris Friday, February 7, 2025, 12 ...

Immunology superstar Dupixent, which first brought Regeneron and Sanofi together in 2007, has entered its megablockbuster era ...

Earnings Call Transcript January 30, 2025 Sanofi misses on earnings expectations. Reported EPS is $0.7 EPS, expectations were ...

Head of Investor Relations Welcome to the Q4 and full year 2024 conference call for investors and analysts. As usual, you can find the slides on sanofi.com. Please turn to Slide 3. Here we have the ...

SINGAPORE: As a grassroots leader for more than a decade, Mr Raymond Poh is no stranger to noise complaints. Whether it is the sweet melody of a violin, the jarring sound of drilling in a home ...

The CEO discussed the success of Dupixent and the remarkable achievement of over $13 billion in global sales in 2024, highlighting its commercial advantage and setting a milestone for Sanofi.

One key stat that many focused on during and after the game, though, was the penalties. The Chiefs were called for just four penalties for 29 yards while the Texans were hit with eight penalties ...

With less frequent dosing, Ebglyss is expected to compete fiercely with Dupixent, a treatment that racked up over $13 billion in sales last year. On Jan. 15, the FDA approved Lilly's Omvoh for the ...

The company said the new policy was a response to complaints by civil society groups and was formulated “in line with local social sensibilities.” Oyo’s move spurred memes and a backlash on ...

The first biologic to enter the COPD market, Dupixent (dupilumab), has paved the way for competitors, demonstrating significant efficacy in reducing exacerbations. Dupixent’s success has ...